1. Home
  2. BCDA vs BREA Comparison

BCDA vs BREA Comparison

Compare BCDA & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • BREA
  • Stock Information
  • Founded
  • BCDA N/A
  • BREA 2022
  • Country
  • BCDA United States
  • BREA Ireland
  • Employees
  • BCDA N/A
  • BREA N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • BREA Services-Misc. Amusement & Recreation
  • Sector
  • BCDA Health Care
  • BREA Consumer Discretionary
  • Exchange
  • BCDA Nasdaq
  • BREA Nasdaq
  • Market Cap
  • BCDA 7.9M
  • BREA 8.7M
  • IPO Year
  • BCDA N/A
  • BREA 2023
  • Fundamental
  • Price
  • BCDA $2.80
  • BREA $0.62
  • Analyst Decision
  • BCDA Strong Buy
  • BREA
  • Analyst Count
  • BCDA 1
  • BREA 0
  • Target Price
  • BCDA $25.00
  • BREA N/A
  • AVG Volume (30 Days)
  • BCDA 53.2K
  • BREA 41.6K
  • Earning Date
  • BCDA 03-26-2025
  • BREA 01-03-2025
  • Dividend Yield
  • BCDA N/A
  • BREA N/A
  • EPS Growth
  • BCDA N/A
  • BREA N/A
  • EPS
  • BCDA N/A
  • BREA N/A
  • Revenue
  • BCDA $71,000.00
  • BREA $2,872,101.00
  • Revenue This Year
  • BCDA N/A
  • BREA N/A
  • Revenue Next Year
  • BCDA N/A
  • BREA N/A
  • P/E Ratio
  • BCDA N/A
  • BREA N/A
  • Revenue Growth
  • BCDA N/A
  • BREA 2338.69
  • 52 Week Low
  • BCDA $1.63
  • BREA $0.50
  • 52 Week High
  • BCDA $8.85
  • BREA $2.44
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 62.90
  • BREA 38.35
  • Support Level
  • BCDA $2.27
  • BREA $0.60
  • Resistance Level
  • BCDA $2.78
  • BREA $0.67
  • Average True Range (ATR)
  • BCDA 0.24
  • BREA 0.04
  • MACD
  • BCDA 0.03
  • BREA -0.01
  • Stochastic Oscillator
  • BCDA 86.57
  • BREA 13.91

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About BREA Brera Holdings PLC

Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.

Share on Social Networks: